DaxibotulinumtoxinA

Revance Therapeutics Inc (NASDAQ: RVNC) has dropped 9 percent since the start of the year, but it's begun a path to redemption through a new, respected advocate. The Rating Goldman Sachs analysts Dana Flanders and Christopher Staral initiated coverage on Revance with a Buy rating and a $60...